These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29571998)

  • 1. Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing.
    Zhang X; Li Y; Liu C; Wang W; Li M; Lv D; Sun G; Chen H; Dong X; Miao Z; Yao M; Wang K; Tian H
    Lung Cancer; 2018 Apr; 118():27-29. PubMed ID: 29571998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
    Pan Y; Zhang Y; Ye T; Zhao Y; Gao Z; Yuan H; Zheng D; Zheng S; Li H; Li Y; Jin Y; Sun Y; Chen H
    J Thorac Oncol; 2019 Nov; 14(11):2003-2008. PubMed ID: 31382039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
    Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
    Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report.
    Wang Y; Xu Y; Wang X; Sun C; Guo Y; Shao G; Yang Z; Qiu S; Ma K
    Medicine (Baltimore); 2019 Jan; 98(3):e14120. PubMed ID: 30653139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
    Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M
    Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIF5B-RET fusions in lung adenocarcinoma.
    Kohno T; Ichikawa H; Totoki Y; Yasuda K; Hiramoto M; Nammo T; Sakamoto H; Tsuta K; Furuta K; Shimada Y; Iwakawa R; Ogiwara H; Oike T; Enari M; Schetter AJ; Okayama H; Haugen A; Skaug V; Chiku S; Yamanaka I; Arai Y; Watanabe S; Sekine I; Ogawa S; Harris CC; Tsuda H; Yoshida T; Yokota J; Shibata T
    Nat Med; 2012 Feb; 18(3):375-7. PubMed ID: 22327624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
    Hida T; Velcheti V; Reckamp KL; Nokihara H; Sachdev P; Kubota T; Nakada T; Dutcus CE; Ren M; Tamura T
    Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET fusion gene: translation to personalized lung cancer therapy.
    Kohno T; Tsuta K; Tsuchihara K; Nakaoku T; Yoh K; Goto K
    Cancer Sci; 2013 Nov; 104(11):1396-400. PubMed ID: 23991695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
    Lipson D; Capelletti M; Yelensky R; Otto G; Parker A; Jarosz M; Curran JA; Balasubramanian S; Bloom T; Brennan KW; Donahue A; Downing SR; Frampton GM; Garcia L; Juhn F; Mitchell KC; White E; White J; Zwirko Z; Peretz T; Nechushtan H; Soussan-Gutman L; Kim J; Sasaki H; Kim HR; Park SI; Ercan D; Sheehan CE; Ross JS; Cronin MT; Jänne PA; Stephens PJ
    Nat Med; 2012 Feb; 18(3):382-4. PubMed ID: 22327622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance Mechanisms to Targeted Therapies in
    McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
    Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
    [No Abstract]   [Full Text] [Related]  

  • 12. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
    Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.
    Ju YS; Lee WC; Shin JY; Lee S; Bleazard T; Won JK; Kim YT; Kim JI; Kang JH; Seo JS
    Genome Res; 2012 Mar; 22(3):436-45. PubMed ID: 22194472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel PIBF1-RET gene fusion identified from a stage IA lung adenocarcinoma: A case report.
    Zhao W; Sun J; Zhu H; Zhao G
    Medicine (Baltimore); 2023 Jul; 102(29):e34305. PubMed ID: 37478265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
    Liu Y; Liu T; Li N; Wang T; Pu Y; Lin R
    Lung Cancer; 2019 Mar; 129():92-94. PubMed ID: 30797499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifification of a novel LDLR-RET Fusion in Lung Adenocarcinoma.
    Shi G; Luo Y; Yu Z; Wang Y; Zhu B
    Invest New Drugs; 2022 Aug; 40(4):858-860. PubMed ID: 35524867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach.
    Yoon HJ; Sohn I; Cho JH; Lee HY; Kim JH; Choi YL; Kim H; Lee G; Lee KS; Kim J
    Medicine (Baltimore); 2015 Oct; 94(41):e1753. PubMed ID: 26469915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
    Shi M; Wang W; Zhang J; Li B; Lv D; Wang D; Wang S; Cheng D; Ma T
    Cancer Sci; 2022 Jan; 113(1):308-318. PubMed ID: 34710947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.